Gilead Sciences, Inc. (NASDAQ: GILD) is 3.43% higher on its value in year-to-date trading and has touched a low of $62.07 and a high of $87.86 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GILD stock was last observed hovering at around $83.99 in the last trading session, with the day’s loss setting it -0.2%.
Currently trading at $83.79, the stock is 3.65% and 8.74% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 7.98 million and changing -0.24% at the moment leaves the stock 13.82% off its SMA200. GILD registered 11.71% gain for a year compared to 6-month gain of 15.45%. The firm has a 50-day simple moving average (SMA 50) of $77.3138 and a 200-day simple moving average (SMA200) of $73.6379.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 9.22% loss in the last 1 month and extending the period to 3 months gives it a 20.37%, and is 0.89% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.48% over the week and 1.83% over the month.
Gilead Sciences, Inc. (GILD) has around 18000 employees, a market worth around $104.32B and $27.78B in sales. Current P/E ratio is 102.41 and Fwd P/E is 11.64. Profit margin for the company is 3.79%. Distance from 52-week low is 34.99% and -4.64% from its 52-week high. The company has generated returns on investments over the last 12 months (2.64%).
with sales reaching $6.97B over the same period.The EPS is expected to shrink by -43.64% this year, but quarterly earnings will post 9.40% year-over-year. Quarterly sales are estimated to grow 2.50% in year-over-year returns.
Gilead Sciences, Inc. (GILD) Top Institutional Holders
2334.0 institutions hold shares in Gilead Sciences, Inc. (GILD), with institutional investors hold 88.02% of the company’s shares. The shares outstanding are 1.25B, and float is at 1.24B with Short Float at 1.59%. Institutions hold 87.92% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 120.63 million shares valued at $8.28 billion. The investor’s holdings represent 9.6738% of the GILD Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 115.26 million shares valued at $7.91 billion to account for 9.2431 of the shares outstanding. The other top investors are CAPITAL WORLD INVESTORS which holds 76.25 million shares representing 6.1147% and valued at over $5.23 billion, while CAPITAL RESEARCH GLOBAL INVESTORS holds 4.8458 of the shares totaling 60.43 million with a market value of $4.15 billion.
Gilead Sciences, Inc. (GILD) Insider Activity
The most recent transaction is an insider sale by Parsey Merdad, the company’s Chief Medical Officer. SEC filings show that Parsey Merdad sold 21,246 shares of the company’s common stock on Sep 12 ’24 at a price of $84.50 per share for a total of $1.8 million. Following the sale, the insider now owns 0.1 million shares.
Gilead Sciences, Inc. disclosed in a document filed with the SEC on Sep 12 ’24 that Mercier Johanna (Chief Commercial Officer) sold a total of 29,357 shares of the company’s common stock. The trade occurred on Sep 12 ’24 and was made at $83.78 per share for $2.46 million. Following the transaction, the insider now directly holds 78127.0 shares of the GILD stock.
Still, SEC filings show that on Sep 12 ’24, MERDAD V PARSEY (Officer) Proposed Sale 21,246 shares at an average price of $84.50 for $1.8 million. The insider now directly holds shares of Gilead Sciences, Inc. (GILD).
